EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE JUSTIFICATION OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN HER2-POSITIVE BREAST CANCER PATIENTS.O. Yin,R. Wada,H. Kastrissios, M. AbuTarif, T. Garimella,C. Lee,L. Zhang,J. Shahidi, F. LaCretaCLINICAL PHARMACOLOGY & THERAPEUTICS（2019）引用 1|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
